Boston Scientific Wins $19.5M In Stent Patent Case
"We are pleased to see the jury recognize the value of our intellectual property," Boston Scientific Executive Vice President Hank Kucheman said in a statement Wednesday. "This is an important outcome in protecting our market position in small-vessel, drug-eluting stents against infringing products."
The verdict marks the tail end of nearly a decade...
To view the full article, register now.